



Product Catalog



2021

New Products

API	Therapeutic Use	FDF	US DMF	CEP	E DMF	J DMF	K DMF	CA DMF
Efinaconazole	Onychomycosis of the toenail or fingernail		●					
Fluticasone Furoate	Seasonal and perennial allergic rhinitis, COPD		●					
Ibrutinib	Mantle cell lymphoma and Chronic lymphocytic leukemia		●					
Pralidoxime Chloride	Treatment of poisoning by organophosphorus chemicals		●					
Propofol	Sedation & Anesthesia		●	●		●		
Rotigotine	Parkinson's disease		●					
Sugammadex	Vecuronium / Rocuronium Antidote		●					
Tavaborole	Onychomycosis of the toenail or fingernail		●					
Tiotropium Bromide Monohydrate	COPD		●	●				

Commercial Products

API	Therapeutic Use	FDF	US DMF	CEP	E DMF	J DMF	K DMF	CA DMF
Ammonium Lactate	Ichthyosis and Xerosis		●					
Anastrozole	Breast cancer	●			●			
Cetirizine Dihydrochloride	Seasonal and perennial allergic rhinitis	●	●	●		●		●
Cilostazol	Reduction of symptoms of intermittent claudication		●			●	●	
Cisatracurium Besylate	Neuromuscular blocking agent		●	●				●
Donepezil Base	Alzheimer's-type dementia		●		●		●	
Donepezil Hydrochloride	Alzheimer's-type dementia		●		●	●		
Fenofibrate	Hyperlipidemia; Hypertriglyceridemia		●	●		●		●
Fexofenadine Hydrochloride	Allergy symptoms		●					

Products protected by 3rd party intellectual property rights are not manufactured or offered for sale in countries where such activity would constitute a potential infringement of these rights.

API	Therapeutic Use	FDF	US DMF	CEP	E DMF	J DMF	K DMF	CA DMF
Flumazenil	Reversal of sedative effects of benzodiazepines		●	●		●	●	●
Fluticasone Propionate	Asthma, COPD		●	●		●	●	●
Fulvestrant	Breast cancer		●	●				
Granisetron Base	Chemotherapy-induced nausea and vomiting		●					
Granisetron Hydrochloride	Chemotherapy-induced nausea and vomiting	●	●	●		●	●	●
Halobetasol Propionate	Topical anti-inflammatory and antipruritic conditions		●					
Imiquimod	Actinic Keratosis/ Superficial Basal Cell Carcinoma		●					
Midazolam	Sedation; Amnesia; Anesthesia		●	●		●	●	●
Modafinil	Narcolepsy / Obstructive Sleep Apnea		●	●				●
Mometasone Furoate Anhydrous	Asthma		●					
Mometasone Furoate Monohydrate	Allergic Rhinitis		●		●			●
Moxonidine	Hypertension	●		●				
Omeprazole Magnesium	Duodenal and gastric ulcer; Gastroesophageal reflux disease (GERD)		●					
Palonosetron Hydrochloride	Chemotherapy Induced / Post-operative Nausea		●		●	●		
Permethrin	Treatment for scabies		●	●				
Pramipexole Dihydrochloride	Parkinson's disease		●					
Rocuronium Bromide	Neuromuscular blocking agent		●		●			
Temozolomide	Glioblastoma multiforme (GBM)	●	●		●			●
Terbinafine Hydrochloride	Onychomycosis of the toenail or fingernail					●		
Tramadol Hydrochloride	Management of moderate to moderately severe pain		●	●		●	●	●

Under Development

API	Therapeutic Use
Cannabidiol	Treatment of Seizures
Cantharidin	Molluscum Contagiosum
Clascoterone	Acne, Alopecia
Remimazolam	Sedation, Amnesia, Anesthesia
Sitagliptin HCl Sitagliptin Phosphate	Type II Diabetes
Umeclidinium Bromide	COPD

Under Evaluation

API	Therapeutic Use
Ganaxolone	Epilepsy, Postpartum Depression
Plinabulin	Chemotherapy Induced Neutropenia
Relugolix	Uterine Fibroids Prostate Cancer
Ruxolitinib Phosphate	Myelofibrosis, Polycythaemia vera, Graft-versus-host disease
Tirbanibulin	Actinic keratosis
Vilanterol Trifenatate	COPD

Wavelength is a customer-focused backward-integrated world-class developer and manufacturer of Active Pharmaceutical Ingredients (APIs). It is the independent company of choice for pharmaceutical industry leaders that require advanced API solutions and reliable supply to gain sustainable competitive advantage. The company is on the same wavelength as its customers – a partner in tune with the results required to best support their needs. Founded in Israel in 1987, with more than 280 customers in 50 countries, Wavelength produces more than 630 metric tons of commercial products every year, across a wide range of technologies including injectables, inhalables, highly potent, cytotoxic and controlled substances. Its cGMP-compliant facility is a first-class operation recognized for excellence in safety and environmental stewardship. Wavelength has achieved an exceptional track record for more than 30 years with all leading global regulatory authorities, including USFDA, EU-EMA, PMDA, TGA, KFSA, ANVISA and COFEPRIS. The company includes experts in complex chemistry, process development and scale-up, enzymatic reactions, crystalline forms and particle design, spray drying and other bioavailability-enhancing solutions. Wavelength offers end-to-end customized solutions to meet individual customer requirements, including full-spectrum API CDMO services from pre-clinical grams to multi-ton commercial scale – always with uncompromising consistent quality, regulatory compliance and exceptional customer service.



Head Office

Petah Tikva, Israel
Tel: +972-3-577-3880

marketing@wavelengthpharma.com

US Office

NJ, USA
Tel: +1-973-987-3030

EU Office

Barcelona, Spain
Tel: +33-620-26-09-28

India Office

Mumbai, India
Tel: +91-773-837-8643

Plant

Beer Sheva, Israel
Tel: +972-8-650-9111

wavelengthpharma.com

